Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?

Similar documents
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Activity C: ELC Prevention Collaboratives

Active Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.

Screening programmes for Hospital Acquired Infections

FM - Male, 38YO. MRSA nasal swab (+) Due to positive MRSA nasal swab test, patient will be continued on Vancomycin 1500mg IV q12 for MRSA treatment...

MDRO in LTCF: Forming Networks to Control the Problem

Evaluating the Role of MRSA Nasal Swabs

Surveillance of Multi-Drug Resistant Organisms

Success for a MRSA Reduction Program: Role of Surveillance and Testing

Reportable Disease Surveillance & Antibiotic Resistant Bacteria

Antimicrobial stewardship: Quick, don t just do something! Stand there!

Preventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal

The importance of infection control in the era of multi drug resistance

Hospital Acquired Infections in the Era of Antimicrobial Resistance

3/1/2016. Antibiotics --When Less is More. Most Urgent Threats. Serious Threats

Surveillance cultures: Can they help our decisions

Multidrug-resistant Organisms (MDROs): Is the Future to be Feared? Multi-drug Resistant Organisms (MDROs)

Antibiotic Stewardship in the Hospital Setting

Nosocomial Infections: What Are the Unmet Needs

Summary of the latest data on antibiotic resistance in the European Union

Strategies to Prevent Methicillin-Resistant Staphylococcus aureus Transmission and Infection in Acute Care Hospitals: 2014 Update

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

Why should we care about multi-resistant bacteria? Clinical impact and

Get Smart For Healthcare

Infection Control of Emerging Diseases

11/22/2016. Hospital-acquired Infections Update Disclosures. Outline. No conflicts of interest to disclose. Hot topics:

Antimicrobial stewardship in managing septic patients

Horizontal vs Vertical Infection Control Strategies

Antimicrobial Cycling. Donald E Low University of Toronto

Risk of organism acquisition from prior room occupants: A systematic review and meta analysis

Hosted by Dr. Jon Otter, Guys & St. Thomas Hospital, King s College, London A Webber Training Teleclass 1

1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection

Appropriate antimicrobial therapy in HAP: What does this mean?

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?

Collecting and Interpreting Stewardship Data: Breakout Session

Infection Control Manual Residential Care Part 3 Infection Control Standards IC7: 0100 Methicillin Resistant Staphylococcus aureus

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline

Other Enterobacteriaceae

MRSA Control : Belgian policy

Antibiotic usage in nosocomial infections in hospitals. Dr. Birgit Ross Hospital Hygiene University Hospital Essen

Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters

(DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE

MDRO s, Stewardship and Beyond. Linda R. Greene RN, MPS, CIC

Multi-drug resistant microorganisms

GUIDE TO INFECTION CONTROL IN THE HOSPITAL

Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship

Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version

TACKLING THE MRSA EPIDEMIC

What bugs are keeping YOU up at night?

Staphylococcus Aureus

Source: Portland State University Population Research Center (

Lindsay E. Nicolle University of Manitoba Winnipeg, CANADA

Methicillin Resistant Staphylococcus Aureus (MRSA) The drug resistant `Superbug that won t die

Challenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S.

Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship

Risk Factors for Persistent MRSA Colonization in Children with Multiple Intensive Care Unit Admissions

MRSA, VRE, VISA, VRSA: Control of Nosocomial Infection

Antimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services

Multi-Drug Resistant Organisms (MDRO)

GUIDE TO INFECTION CONTROL IN THE HOSPITAL. Antibiotic Resistance

New Drugs for Bad Bugs- Statewide Antibiogram

MDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta

MRSA control strategies in Europekeeping up with epidemiology?

DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA

The International Collaborative Conference in Clinical Microbiology & Infectious Diseases

Bacterial infections complicating cirrhosis

Rise of Resistance: From MRSA to CRE

MAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges

MAJOR ARTICLE. Impact of MRSA Surveillance on Bacteremia CID 2006:43 (15 October) 971

Is biocide resistance already a clinical problem?

Jump Starting Antimicrobial Stewardship

Approval Signature: Original signed by Dr. Michel Tetreault Date of Approval: July Review Date: July 2017

What s New in MRSA? An Update on Legislative Mandates and MRSA in the Obstetrics/ Gynecology Patient

LINEE GUIDA: VALORI E LIMITI

Healthcare-associated Infections and Antimicrobial Use Prevalence Survey

NHSN 2015 Rebaseline and TDH Updates. Ashley Fell, MPH

Surveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at Chiang Mai University Hospital,

Antimicrobial resistance (EARS-Net)

Birgit Ross Hospital Hygiene University Hospital Essen Essen, Germany. Should we screen for multiresistant gramnegative Bacteria?

Lecture Notes: The Importance of Nurse Empowerment. Theme: It is not the Nurses Fault

Healthcare-associated Infections Annual Report March 2015

Burden of disease of antibiotic resistance The example of MRSA. Eva Melander Clinical Microbiology, Lund University Hospital

Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms

Antibiotic Stewardship in LTC What does this mean?

Preventing Clostridium difficile Infection (CDI)

Healthcare-associated Infections Annual Report

SURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS

Konsequenzen für Bevölkerung und Gesundheitssysteme. Stephan Harbarth Infection Control Program

11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose

MRSA in the United Kingdom status quo and future developments

original article infection control and hospital epidemiology october 2009, vol. 30, no. 10

The Core Elements of Antibiotic Stewardship for Nursing Homes

Implementing Antibiotic Stewardship in Rural and Critical Access Hospitals

Successful stewardship in hospital settings

Dr Nata Menabde Executive Director World Health Organization Office at the United Nations Global action plan on antimicrobial resistance

Two (II) Upon signature

Responders as percent of overall members in each category: Practice: Adult 490 (49% of 1009 members) 57 (54% of 106 members)

Healthcare-associated infections surveillance report

NHS Scotland MRSA Screening Pathfinder Programme

Pneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center

HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE

Transcription:

Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and Prevention February 25, 2010 Antimicrobial Resistance is an Important Public Health Problem

Resistant pathogens lead to higher health care costs because they often require more expensive drugs and extended hospital stays. The total cost to U.S. society is nearly $5 billion annually MRSA is an Important Part of The Antimicrobial Resistance Problem Prevalence of Multidrug-Resistance Among HAI Pathogens Reported to NHSN, 2006-2007 Pathogen MRSA VRE Carbapenem-resistant P. aeruginosa Extended-spectrum cephalosporinresistant K. pneumoniae Extended-spectrum cephalosporinresistant E. coli Carbapenem-resistant A. baumannii, K. pneumoniae, K. oxytoca, and E. coli % of all HAI 8% 4% 2% 1% 0.5% 0.5%

Healthcare-Associated MRSA Infections Are Expensive Medical plus Societal costs for a Chicago Teaching Hospital: $60,984 (2008 dollars) per infection Almost $5 million total costs attributable to MRSA per year Roberts RR et al. Clinical Infectious Diseases 2009;49:1175-84 Outcomes for MRSA Infection are Worse than For MSSA Infection Summary of Unadjusted Results of Studies Comparing Mortality of MRSA and MSSA Bacteremia Cosgrove et al. Clinical Infectious Diseases 2003:36;53-59 Limitations in Therapeutic Options For MRSA Exist, and Appear to Be Getting Worse Vancomycin susceptibility in MRSA is decreasing over time Infections caused by vancomycin-susceptible MRSA organisms with MICs of 1 mg/ml appear to respond less effectively to vancomycin than do infections caused by organisms with MICs of <1 mg/ml. Reports of linezolid and daptomycin resistance among MRSA poses concern for future durability of these agents Sakoulas and Moellering. Clinical Infectious Diseases 2008; 46:S360 7

MRSA is an Important Part of The Antimicrobial Resistance Problem Epidemiology of Healthcare-Associated MRSA The emergence of Healthcare-Associated MRSA has been due to transmission of relatively few clones, not de novo selection from susceptible S. aureus strains

Acquistion of MRSA Colonization Has Consequences that Extend Beyond One Hospitalization Patients can carry MRSA with them for months or years Infections may develop following hospital discharge, or during subsequent admissions 29% of patients with new MRSA acquisition developed infection in the subsequent 18 months, half of these following hospital discharge Huang and Platt. Clin Infect Dis 2004;36:281 When patients are readmitted to the same or another healthcare facility, they serve as a potential reservoir of transmission Healthcare Facilities Serve as Amplifiers of MRSA Transmission

MRSA Carriage Rates at Admission, Veterans Hospitals 2006-2007 (n=14) MRSA Carriage Rates in General Population=1.5% Healthcare Facilities Serve as Amplifiers of MRSA Transmission Two Strategies for Preventing Healthcare-Associated MRSA Infection Preventing acquisition of MRSA colonization (i.e. preventing transmission) Preventing Infection Among Patients Colonized with MRSA (i.e. preventing endogenous infection)

Overall rate reduction of 68% MMWR 2005;54:1013-6 Michigan Keystone ICU Project Overall rate reduction of 67% Provonost et al. NEJM 2006;355:2725-2732 Trends in Incidence of Central Line Associated Bloodstream Infections by Intensive Care Unit Type National Nosocomial Infections Surveillance System, 1997-2004; National Healthcare Safety Network, 2006-2007 Burton et al. JAMA. 2009;301(7):727-736

Trends in %MRSA and Rates of MRSA Central Line- Associated Bloodstream Infections (CLABSI) United States, 1997-2007 0.8 Pooled Mean CLABSI Rate per 1,000 Central Line Days or %MRSA 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Proportion of S. aureus nonsusceptible to methicillin +25.8% * Rate of CLABSI caused by MRSA o -49.6%** 2 0 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Year Burton et al. JAMA. 2009;301(7):727-736 Preventing hospital-onset device and procedure-associated infections, while important, is not a sufficient approach to the problem of healthcare-associated MRSA Does not directly address the antimicrobial resistance issue Does not address the majority of healthcare-associated MRSA infections that occur Trends in %MRSA and Rates of MRSA Central Line- Associated Bloodstream Infections (CLABSI) United States, 1997-2007 0.8 Pooled Mean CLABSI Rate per 1,000 Central Line Days or %MRSA 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Proportion of S. aureus nonsusceptible to methicillin +25.8% * Rate of CLABSI caused by MRSA o -49.6%** 2 0 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Year **P<0.0001 Burton et al. JAMA 2009; 301:727-36

Most Healthcare-Associated MRSA Infections Have Their Onset Outside of the Hospital 28% 14% 59% Community-Associated Healthcare-Associated (community-onset) Healthcare-Associated (hospital-onset) Klevens et al JAMA 2007;298:1763-71

Preventing Transmission is Critically Important in Controlling Healthcare- Associated MRSA How Do We Prevent MRSA Transmission in the Healthcare Setting? General approach Optimizing antimicrobial use Standard precautions for all patients Targeted approach Additional infection control measures to prevent transmission from colonized individuals (e.g. Contact Precautions)

Antibiotic Management alone does not appear to effectively control MRSA transmission Use of Standard Precautions alone is not as effective at preventing transmission in comparison to strategies that use additional infection control precautions (e.g. Contact Precautions) Comparing Rates of MRSA Transmission: Standard Precautions vs. Contact Precautions Source Isolated Unisolated Transmissions 5 10 Patient-days 558 71.5 Rates 0.009 0.140 RR=15.6, 95% CI=5.3-45.6, p<0.0001 Jernigan, et al. Am J Epi 1996;143:496-504.

Vriens et al. Infect Control Hospital Epidemiol 2002;23:491 Between 1992-2001, screening cultures taken twice weekly on all patients in SICU 3 MRSA-colonized patients admitted and isolated at admission Single transmission documented 3 MRSA-colonized patients admitted, but not isolated at time of admission 37 transmissions documented Iceberg Effect 76-85% of MRSA carriers admitted to acute care hospitals will remain unrecognized if clinical cultures alone are used to identify them Salgado et al. Infect Control Hosp Epidemiol 2006; 27:116-121 Lucet et al. Infect Control Hosp Epidemiol 2005;26:121-126 Jernigan et al. Infect Control Hosp Epidemiol 2003;24:409-414 What is the Evidence that Use of Active Surveillance is Effective?

Post-intervention: ICU MRSA bacteremia rate declined 80%, p<.001 Non-ICU bacteremia rate declined 67%, p=.002 No decline in MSSA bacteremia Huang et al. Clin Infect Dis 2006;43:971-978 Universal Surveillance for Methicillin-Resistant Staphylococcus aureus in 3 Affiliated Hospitals Robicsek, A. et. al. Ann Intern Med 2008;148:409-418 Hospital-based Measures May Prevent Post-Discharge Infections 20 Robicsek et al. Ann Int Med 2008 MRSA Infections per 10,000 admissions 15 10 5 No surveillance ICU surveillance Universal surveillance 0 During 1-30 31-60 61-90 91-120 120-150 151-180 admission Days since most recent admission

MRSA Incidence: Pittsburgh VA Hospital, October 1999 to November 2008 5 MRSA per 1000 Patient Days 4 3 2 1 0 1 7 13 19 25 31 37 43 49 55 61 67 73 79 85 91 97 103 109 Month Observed MRSA per 1000 Patient Days Oct. 1999 Predicted MRSA per 1000 Patient Days with ITS Model Nov. 2008 Proportion of Clinical S. aureus Isolates Resistant to Methicillin, Pittsburgh VA Hospital, 1999-2008 MRSA/All S. aureus cultures 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 1 8 15 22 29 36 43 50 57 64 71 78 85 92 99 106 observed 30% decrease Month (p<.001) expected Admission Prevalence of MRSA Carriage Based on Clinical Cultures, Pittsburgh VA Hospital, 1999-2008 10 9 Percent of Admissions 8 7 6 5 4 3 2 1 0 1 5 9 13 17 21 25 29 33 37 41 45 49 53 57 61 65 69 73 77 81 85 89 93 97 101 105 109 Observed Expected

Results of a Multicenter MRSA Prevention Collaborative Intervention - 3 hospitals in geographically distinct areas of US (Montana, Pennsylvania, Kentucky) - Active Surveillance in ICUs, Contact Precautions for MRSA carriers, Hand hygiene promotion, Systems/Behavioral Change Strategies - ICU intervention focus, housewide evaluation - 18 months post-intervention - Reduction in MRSA incidence in all three hospitals (26%, 31, 62%, pooled result p<.001) - Increase % S. aureus susceptible to methicillin (7%, 15%, 28%, pooled result p=.02) Ellingston et al. Abstract Presentation, SHEA 2009 Preventing Surgical-site infections in nasal carriers of Staphylococcus aureus Using Active Surveillance: Randomized Double-Blind, Placebo Controlled Trial Bode et al. N Engl J Med 2010;362:9-17 Conclusions of Two Systematic Reviews on Use of Active Surveillance and Isolation for Controlling MRSA There is evidence that concerted efforts that include isolation can reduce MRSA even in endemic settings. Current isolation measures recommended in national guidelines should continue to be applied until further research establishes otherwise. Cooper et al. BMJ 2004;329;533 Evidence from multiple observational studies suggest that use of ASCs reduces the incidence of MRSA infection McGinigle et al. Clin Infect Dis 2008;46:1717-25

Summary We are currently experiencing a crisis in antimicrobial resistance in healthcare, and MRSA is a major part of the problem Our response needs to be multi-faceted, and must include both measures to prevent transmission and prevent infections among MRSA-colonized individuals Summary (continued) Effective prevention of transmission has benefits that persist beyond a single hospitalization, and is currently the most logical strategy for preventing the downstream adverse effects of healthcareacquired MRSA acquisition Usual facility-based surveillance strategies do not capture these downstream events, and therefore grossly underestimate the burden of consequences resulting from healthcareacquired MRSA acquisition Summary (continued) The weight of the current evidence suggests that strategies that use active surveillance are more effective at preventing epidemic and endemic MRSA transmission than strategies that do not Given the current burden of the MRSA problem and evidence suggesting uncontrolled transmission in healthcare settings, active surveillance-based strategies should be widely employed The optimal strategy for implementation of active surveillance has yet to be fully determined (e.g. universal screening versus screening in targeted settings and patient populations)